Pages that link to "Q27320923"
The following pages link to Immunogenic profiling in mice of a HIV/AIDS vaccine candidate (MVA-B) expressing four HIV-1 antigens and potentiation by specific gene deletions (Q27320923):
Displaying 50 items.
- A candidate HIV/AIDS vaccine (MVA-B) lacking vaccinia virus gene C6L enhances memory HIV-1-specific T-cell responses (Q21135240) (← links)
- Retracted: Comparative Expression Profile of miRNA and mRNA in Primary Peripheral Blood Mononuclear Cells Infected with Human Immunodeficiency Virus (HIV-1) (Q21560946) (← links)
- Poxvirus vectors as HIV/AIDS vaccines in humans (Q26995078) (← links)
- The evolution of poxvirus vaccines (Q26995905) (← links)
- A Chimeric HIV-1 gp120 Fused with Vaccinia Virus 14K (A27) Protein as an HIV Immunogen (Q27302081) (← links)
- Deletion of the vaccinia virus gene A46R, encoding for an inhibitor of TLR signalling, is an effective approach to enhance the immunogenicity in mice of the HIV/AIDS vaccine candidate NYVAC-C (Q27306437) (← links)
- Vaccine efficacy against malaria by the combination of porcine parvovirus-like particles and vaccinia virus vectors expressing CS of Plasmodium (Q28730541) (← links)
- A human multi-epitope recombinant vaccinia virus as a universal T cell vaccine candidate against influenza virus (Q31037728) (← links)
- Dendritic cells exposed to MVA-based HIV-1 vaccine induce highly functional HIV-1-specific CD8(+) T cell responses in HIV-1-infected individuals (Q33916776) (← links)
- Improving the MVA vaccine potential by deleting the viral gene coding for the IL-18 binding protein (Q34182371) (← links)
- Systems analysis of MVA-C induced immune response reveals its significance as a vaccine candidate against HIV/AIDS of clade C. (Q34247289) (← links)
- Adjuvant-like effect of vaccinia virus 14K protein: a case study with malaria vaccine based on the circumsporozoite protein (Q34274515) (← links)
- High quality long-term CD4+ and CD8+ effector memory populations stimulated by DNA-LACK/MVA-LACK regimen in Leishmania major BALB/c model of infection (Q34310410) (← links)
- Deletion of the viral anti-apoptotic gene F1L in the HIV/AIDS vaccine candidate MVA-C enhances immune responses against HIV-1 antigens (Q34465228) (← links)
- Use of RT-defective HIV virions: new tool to evaluate specific response in chronic asymptomatic HIV-infected individuals (Q34630184) (← links)
- MicroRNA regulation and its effects on cellular transcriptome in human immunodeficiency virus-1 (HIV-1) infected individuals with distinct viral load and CD4 cell counts (Q34747583) (← links)
- Improving Adaptive and Memory Immune Responses of an HIV/AIDS Vaccine Candidate MVA-B by Deletion of Vaccinia Virus Genes (C6L and K7R) Blocking Interferon Signaling Pathways (Q34796206) (← links)
- Virological and immunological characterization of novel NYVAC-based HIV/AIDS vaccine candidates expressing clade C trimeric soluble gp140(ZM96) and Gag(ZM96)-Pol-Nef(CN54) as virus-like particles. (Q34991112) (← links)
- Deletion of Fifteen Open Reading Frames from Modified Vaccinia Virus Ankara Fails to Improve Immunogenicity (Q35656345) (← links)
- Rodent models for HIV-associated neurocognitive disorders. (Q35803957) (← links)
- Removal of vaccinia virus genes that block interferon type I and II pathways improves adaptive and memory responses of the HIV/AIDS vaccine candidate NYVAC-C in mice (Q35943846) (← links)
- Comparable polyfunctionality of ectromelia virus- and vaccinia virus-specific murine T cells despite markedly different in vivo replication and pathogenicity (Q36155548) (← links)
- Deletion of specific immune-modulatory genes from modified vaccinia virus Ankara-based HIV vaccines engenders improved immunogenicity in rhesus macaques (Q36397581) (← links)
- Interleukin-1β receptor expressed by modified vaccinia virus Ankara interferes with interleukin-1β activity produced in various virus-infected antigen-presenting cells (Q36741144) (← links)
- Attenuated and replication-competent vaccinia virus strains M65 and M101 with distinct biology and immunogenicity as potential vaccine candidates against pathogens. (Q36911682) (← links)
- Enhancing poxvirus vectors vaccine immunogenicity. (Q36978452) (← links)
- High, broad, polyfunctional, and durable T cell immune responses induced in mice by a novel hepatitis C virus (HCV) vaccine candidate (MVA-HCV) based on modified vaccinia virus Ankara expressing the nearly full-length HCV genome (Q36978998) (← links)
- Increased attenuation but decreased immunogenicity by deletion of multiple vaccinia virus immunomodulators (Q37255121) (← links)
- Involvement of the cellular phosphatase DUSP1 in vaccinia virus infection. (Q37308720) (← links)
- Deletion of the vaccinia virus N2L gene encoding an inhibitor of IRF3 improves the immunogenicity of modified vaccinia virus Ankara expressing HIV-1 antigens. (Q37643731) (← links)
- A novel poxvirus-based vaccine, MVA-CHIKV, is highly immunogenic and protects mice against chikungunya infection. (Q37643733) (← links)
- Clinical applications of attenuated MVA poxvirus strain. (Q38156198) (← links)
- Immune modulation by virus-encoded secreted chemokine binding proteins (Q38384475) (← links)
- Safety and immunogenicity of a modified vaccinia Ankara-based HIV-1 vaccine (MVA-B) in HIV-1-infected patients alone or in combination with a drug to reactivate latent HIV-1. (Q38415577) (← links)
- Safety and immunogenicity of a modified pox vector-based HIV/AIDS vaccine candidate expressing Env, Gag, Pol and Nef proteins of HIV-1 subtype B (MVA-B) in healthy HIV-1-uninfected volunteers: A phase I clinical trial (RISVAC02). (Q38484762) (← links)
- Use of functional genomics to understand replication deficient poxvirus-host interactions (Q38620980) (← links)
- The HIV/AIDS vaccine candidate MVA-B administered as a single immunogen in humans triggers robust, polyfunctional, and selective effector memory T cell responses to HIV-1 antigens. (Q38725610) (← links)
- Vector replication and expression of HIV-1 antigens by the HIV/AIDS vaccine candidate MVA-B is not affected by HIV-1 protease inhibitors (Q39338087) (← links)
- Immunogenicity and efficacy of DNA/MVA HIV vaccines in rhesus macaque models (Q40071705) (← links)
- HIV/AIDS Vaccine Candidates Based on Replication-Competent Recombinant Poxvirus NYVAC-C-KC Expressing Trimeric gp140 and Gag-Derived Virus-Like Particles or Lacking the Viral Molecule B19 That Inhibits Type I Interferon Activate Relevant HIV-1-Speci (Q40339467) (← links)
- A Phase I Randomized Therapeutic MVA-B Vaccination Improves the Magnitude and Quality of the T Cell Immune Responses in HIV-1-Infected Subjects on HAART. (Q40919787) (← links)
- Immune Modulation of NYVAC-Based HIV Vaccines by Combined Deletion of Viral Genes that Act on Several Signalling Pathways (Q47252143) (← links)
- Distinct Immunogenicity and Efficacy of Poxvirus-based Vaccine Candidates against Ebola Virus expressing GP and VP40 Proteins. (Q51784219) (← links)
- The Gene of Goatpox Virus Encodes an Inhibitor of NF-κB and Apoptosis and May Serve as an Improved Insertion Site To Generate Vectored Live Vaccine (Q56556724) (← links)
- Removal of the C6 Vaccinia Virus Interferon-β Inhibitor in the Hepatitis C Vaccine Candidate MVA-HCV Elicited in Mice High Immunogenicity in Spite of Reduced Host Gene Expression (Q56987707) (← links)
- A Vaccine Based on a Modified Vaccinia Virus Ankara Vector Expressing Zika Virus Structural Proteins Controls Zika Virus Replication in Mice (Q59349966) (← links)
- Deletion of Vaccinia Virus A40R Gene Improves the Immunogenicity of the HIV-1 Vaccine Candidate MVA-B (Q89633807) (← links)
- Novel Modified Vaccinia Virus Ankara Vector Expressing Anti-apoptotic Gene B13R Delays Apoptosis and Enhances Humoral Responses (Q90434144) (← links)
- Viral vector and route of administration determine the ILC and DC profiles responsible for downstream vaccine-specific immune outcomes (Q91408185) (← links)
- An MVA Vector Expressing HIV-1 Envelope under the Control of a Potent Vaccinia Virus Promoter as a Promising Strategy in HIV/AIDS Vaccine Design (Q91813907) (← links)